Presentazione standard di...
Transcript of Presentazione standard di...
![Page 1: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/1.jpg)
Milano, 15 giugno 2018
Lung Cancer Session
Highlights
Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona
![Page 2: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/2.jpg)
• Advisory Boards/Honoraria/Speakers’ fee/Consultant for: – Astra-Zeneca, Eli-Lilly, Boeringher Ingelheim, BMS
• Research Support/Grants from: – A.I.R.C. (Associazione Italiana Ricerca sul Cancro)
– I.A.S.L.C. (International Association for the Study of Lung Cancer)
– Fondazione Cariverona
– Open Innovation
– Astra-Zeneca
Disclosures
![Page 3: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/3.jpg)
Immunotherapy in First Line
KEYNOTE-042
CheckMate-227
[PD-L1<1%]
IMpower150 [OS]
IMpower131
KEYNOTE-407
Steroids
NSCLC
Non-Sq
Sq
![Page 4: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/4.jpg)
Lopes G, ASCO 2018
NSCLC - PD-L1 ≥1% [KEYNOTE-042]
![Page 5: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/5.jpg)
Lopes G, ASCO 2018
OS TPS ≥ 50%
OS TPS ≥ 20%
OS TPS ≥ 1%
![Page 6: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/6.jpg)
Lopes G, ASCO 2018
NSCLC - PD-L1 ≥1% [KEYNOTE-042]
![Page 7: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/7.jpg)
PFS TPS ≥ 50%
PFS TPS ≥ 20%
PFS TPS ≥ 1%
Lopes G, ASCO 2018
![Page 8: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/8.jpg)
Lopes G, ASCO 2018
ORR for TPS 1-49%: pembro 16.6%
versus 21.7% for CT
NSCLC - PD-L1 ≥1% [KEYNOTE-042]
![Page 9: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/9.jpg)
Lopes G, ASCO 2018
NSCLC - PD-L1 ≥1% [KEYNOTE-042]
Any grade thyroiditis (18%) and
pneumonitis (8%)
![Page 10: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/10.jpg)
Lopes G, ASCO 2018
NSCLC - PD-L1 ≥1% [KEYNOTE-042]
![Page 11: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/11.jpg)
NSCLC - PD-L1 < 1% [CHECKMATE-227]
Borghaei H, ASCO 2018
1. Nivo + CT versus CT in patients with PD-L1 < 1% 2. Subset analysis according to TMB status (55%)
![Page 12: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/12.jpg)
Borghaei H, ASCO 2018
NSCLC - PD-L1 < 1% [CHECKMATE-227]
![Page 13: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/13.jpg)
Borghaei H, ASCO 2018
NSCLC - PD-L1 < 1% [CHECKMATE-227]
![Page 14: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/14.jpg)
NSCLC - PD-L1 < 1% [CHECKMATE-227]
Borghaei H, ASCO 2018
![Page 15: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/15.jpg)
NSCLC - PDL1 < 1% [CHECKMATE-227]
Borghaei H, ASCO 2018
![Page 16: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/16.jpg)
Non-Squamous NSCLC [IMpower150]
Socinski M, ASCO 2018
Co-Primary Endpoint Analysis
![Page 17: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/17.jpg)
Non-Squamous NSCLC [IMpower150]
Socinski M, ASCO 2018
![Page 18: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/18.jpg)
Non-Squamous NSCLC [IMpower150]
Socinski M, ASCO 2018
![Page 19: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/19.jpg)
Non-Squamous NSCLC [IMpower150]
Socinski M, ASCO 2018
![Page 20: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/20.jpg)
Non-Squamous NSCLC [IMpower150]
Socinski M, ASCO 2018
![Page 21: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/21.jpg)
Non-Squamous NSCLC [IMpower150]
Socinski M, ASCO 2018
After progression to standard TKI therapyl
![Page 22: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/22.jpg)
Squamous NSCLC [IMpower131]
Jotte R, ASCO 2018
![Page 23: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/23.jpg)
Squamous NSCLC [IMpower131]
Jotte R, ASCO 2018
![Page 24: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/24.jpg)
Squamous NSCLC [IMpower131]
Jotte R, ASCO 2018
HR 1.34 In PD-L1 low (TC1/2 or IC1/2) OS has an
opposite trend
![Page 25: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/25.jpg)
Squamous NSCLC [IMpower131]
Jotte R, ASCO 2018
![Page 26: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/26.jpg)
Squamous NSCLC [IMpower131]
Jotte R, ASCO 2018
![Page 27: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/27.jpg)
Squamous NSCLC [KEYNOTE-407]
Paz-Ares L, ASCO 2018
![Page 28: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/28.jpg)
Squamous NSCLC [KEYNOTE-407]
Paz-Ares L, ASCO 2018
![Page 29: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/29.jpg)
Squamous NSCLC [KEYNOTE-407]
Paz-Ares L, ASCO 2018
![Page 30: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/30.jpg)
Squamous NSCLC [KEYNOTE-407]
Paz-Ares L, ASCO 2018
![Page 31: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/31.jpg)
Squamous NSCLC [KEYNOTE-407]
Paz-Ares L, ASCO 2018
![Page 32: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/32.jpg)
Arbour KC, ASCO 2018
Steroids & Immunotherapy
85% >10mg
![Page 33: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/33.jpg)
Oncogene Addicted
ARCHER 1050 [OS]
NEJ009 [OS]
NEJ026
JO25567 [OS]
ImmunoTarget
Erlotinib + Beva
![Page 34: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/34.jpg)
Mok T, ASCO 2018
Oncogene Addicted [ARCHER 1050]
![Page 35: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/35.jpg)
Mok T, ASCO 2018
Oncogene Addicted [ARCHER 1050]
![Page 36: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/36.jpg)
Mok T, ASCO 2018
Relevant ≥G3 toxicities (diarrhea, paronychia, dermatitis, stomatitis,..)
63% (vs 41%)
Oncogene Addicted [ARCHER 1050]
![Page 37: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/37.jpg)
Oncogene Addicted [ARCHER 1050]
Mok T, ASCO 2018
![Page 38: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/38.jpg)
Oncogene Addicted [NEJ009]
Nakamura A, ASCO 2018
![Page 39: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/39.jpg)
Nakamura A, ASCO 2018
PFS1
PFS2
OS
![Page 40: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/40.jpg)
Oncogene Addicted [NEJ009]
Relevant ≥G3 toxicities (hematological, liver dysfunction,
anorexia, fatigue,..)
Nakamura A, ASCO 2018
![Page 41: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/41.jpg)
Oncogene Addicted [NEJ009]
Nakamura A, ASCO 2018
![Page 42: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/42.jpg)
• 30% vs 19% discontinuation
• 56% vs 37% ≥ G3 toxicities
• 22% HTN and 7% proteinuria G3
Sequist L, ASCO 2018
Oncogene Addicted [NEJ026]
![Page 43: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/43.jpg)
Yamamoto N, ASCO 2018
• 41% discontinuation • 61% HTN and 8%
proteinuria G3
Oncogene Addicted [JO25567]
![Page 44: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/44.jpg)
Oncogene Addicted [ImmunoTarget]
Mazieres J, ASCO 2018
N = 551
![Page 45: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/45.jpg)
Others..
Lymph Node Kit Lung Cancer Screening
![Page 46: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/46.jpg)
Lymph Node Collection Kit for NSCLC
Osarogiagbon RU, ASCO 2018
Over 1,100 resections and 32 surgeons were involved
![Page 47: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/47.jpg)
Lung Cancer Screening
Pham D, ASCO 2018
![Page 48: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/48.jpg)
Lung Cancer Screening
Pham D, ASCO 2018
![Page 49: Presentazione standard di PowerPointmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...paronychia, dermatitis, stomatitis,..) 63% (vs 41%) Oncogene Addicted [ARCHER 1050] Oncogene](https://reader034.fdocuments.us/reader034/viewer/2022042112/5e8e913ff7852e421e584c5b/html5/thumbnails/49.jpg)
GRAZIE
PER
L’ATTENZIONE